1. Sakane T, Takeno M, Suzuki N, Inaba G. Behçet’s disease. N Engl J Med 1999;341:1284–1291.

2. Kaklamani VG, Kaklamanis PG. Treatment of Behçet’s disease--an update. Semin Arthritis Rheum 2001;30:299–312.

3. Kim DH, Cheon JH. Intestinal Behçet’s disease: a true inflammatory bowel disease or merely an intestinal complication of systemic vasculitis? Yonsei Med J 2016;57:22–32.

4. Suzuki Y, Hagiwara T, Kobayashi M, Morita K, Shimamoto T, Hibi T. Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behçet’s disease: results from a large real-world observational study. Intest Res 2021;19:301–312.

5. Song EM, Yang SK. Natural history of inflammatory bowel disease: a comparison between the East and the West. Intest Res 2022;20:418–430.

6. Grigg EL, Kane S, Katz S. Mimicry and deception in inflammatory bowel disease and intestinal behçet disease. Gastroenterol Hepatol (N Y) 2012;8:103–112.

7. Cheon JH. Advances in management of intestinal Behçet’s disease: a perspective from gastroenterologists. J Rheum Dis 2021;28:4–16.

8. Koh SJ, Hong SN, Park SK, et al. Korean clinical practice guidelines on biologics for moderate to severe Crohn’s disease. Intest Res 2023;21:43–60.

9. Na SY, Choi CH, Song EM, et al. Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis. Intest Res 2023;21:61–87.

10. Banner MP. Genitourinary complications of inflammatory bowel disease. Radiol Clin North Am 1987;25:199–209.

11. Dincer MT, Dincer ZT, Bakkaloglu OK, et al. Renal manifestations in inflammatory bowel disease: a cohort study during the biologic era. Med Sci Monit 2022;28:e936497.

12. Fagagnini S, Heinrich H, Rossel JB, et al. Risk factors for gallstones and kidney stones in a cohort of patients with inflammatory bowel diseases. PLoS One 2017;12:e0185193.

13. Lammert F, Gurusamy K, Ko CW, et al. Gallstones. Nat Rev Dis Primers 2016;2:16024.

14. Heaton KW. Disturbances of bile acid metabolism in intestinal disease. Clin Gastroenterol 1977;6:69–89.

15. Dowling RH, Bell GD, White J. Lithogenic bile in patients with ileal dysfunction. Gut 1972;13:415–420.

16. Brink MA, Slors JF, Keulemans YC, et al. Enterohepatic cycling of bilirubin: a putative mechanism for pigment gallstone formation in ileal Crohn’s disease. Gastroenterology 1999;116:1420–1427.

17. Damião AO, Sipahi AM, Vezozzo DP, Gonçalves PL, Fukui P, Laudanna AA. Gallbladder hypokinesia in Crohn’s disease. Digestion 1997;58:458–463.

18. Mayans L. Nephrolithiasis. Prim Care 2019;46:203–212.

19. McConnell N, Campbell S, Gillanders I, Rolton H, Danesh B. Risk factors for developing renal stones in inflammatory bowel disease. BJU Int 2002;89:835–841.

20. Coe FL, Parks JH, Asplin JR. The pathogenesis and treatment of kidney stones. N Engl J Med 1992;327:1141–1152.

21. Cheon JH, Kim ES, Shin SJ, et al. Development and validation of novel diagnostic criteria for intestinal Behçet’s disease in Korean patients with ileocolonic ulcers. Am J Gastroenterol 2009;104:2492–2499.

22. Stinton LM, Myers RP, Shaffer EA. Epidemiology of gallstones. Gastroenterol Clin North Am 2010;39:157–169vii.

23. Chang YR, Jang JY, Kwon W, et al. Changes in demographic features of gallstone disease: 30 years of surgically treated patients. Gut Liver 2013;7:719–724.

24. Sohgaura A, Bigoniya P. A review on epidemiology and etiology of renal stone. Am J Discov Dev 2017;7:54–62.

25. Parente F, Pastore L, Bargiggia S, et al. Incidence and risk factors for gallstones in patients with inflammatory bowel disease: a large case-control study. Hepatology 2007;45:1267–1274.

26. Fraquelli M, Losco A, Visentin S, et al. Gallstone disease and related risk factors in patients with Crohn disease: analysis of 330 consecutive cases. Arch Intern Med 2001;161:2201–2204.

27. Zhang FM, Xu CF, Shan GD, Chen HT, Xu GQ. Is gallstone disease associated with inflammatory bowel diseases? A meta-analysis. J Dig Dis 2015;16:634–641.

28. Lorusso D, Leo S, Mossa A, Misciagna G, Guerra V. Cholelithiasis in inflammatory bowel disease. A case-control study. Dis Colon Rectum 1990;33:791–794.

29. Jeong YH, Kim KO, Lee HC, et al. Gallstone prevalence and risk factors in patients with ulcerative colitis in Korean population. Medicine (Baltimore) 2017;96:e7653.

30. Bennett RC, Hughes ES. Urinary calculi and ulcerative colitis. Br Med J 1972;2:494–496.

31. Knudsen L, Marcussen H, Fleckenstein P, Pedersen EB, Jarnum S. Urolithiasis in chronic inflammatory bowel disease. Scand J Gastroenterol 1978;13:433–436.

32. Gelzayd EA, Breuer RI, Kirsner JB. Nephrolithiasis in inflammatory bowel disease. Am J Dig Dis 1968;13:1027–1034.

33. Maratka Z, Nedbal J. Urolithiasis as a complication of the surgical treatment of ulcerative colitis. Gut 1964;5:214–217.

34. Kennedy HJ, Al-Dujaili EA, Edwards CR, Truelove SC. Water and electrolyte balance in subjects with a permanent ileostomy. Gut 1983;24:702–705.

35. Hutchinson R, Tyrrell PN, Kumar D, Dunn JA, Li JK, Allan RN. Pathogenesis of gall stones in Crohn’s disease: an alternative explanation. Gut 1994;35:94–97.

36. Parks JH, Worcester EM, O’Connor RC, Coe FL. Urine stone risk factors in nephrolithiasis patients with and without bowel disease. Kidney Int 2003;63:255–265.

37. Kane S. Urogenital complications of Crohn’s disease. Am J Gastroenterol 2006;101(12 Suppl):S640–S643.

38. Mukewar S, Hall P, Lashner BA, Lopez R, Kiran RP, Shen B. Risk factors for nephrolithiasis in patients with ileal pouches. J Crohns Colitis 2013;7:70–78.

39. Cury DB, Moss AC, Schor N. Nephrolithiasis in patients with inflammatory bowel disease in the community. Int J Nephrol Renovasc Dis 2013;6:139–142.

40. Shea JA, Berlin JA, Escarce JJ, et al. Revised estimates of diagnostic test sensitivity and specificity in suspected biliary tract disease. Arch Intern Med 1994;154:2573–2581.

41. Barakos JA, Ralls PW, Lapin SA, et al. Cholelithiasis: evaluation with CT. Radiology 1987;162:415–418.

42. Coursey CA, Casalino DD, Remer EM, et al. ACR Appropriateness Criteria® acute onset flank pain--suspicion of stone disease. Ultrasound Q 2012;28:227–233.

43. Fulgham PF, Assimos DG, Pearle MS, Preminger GM. Clinical effectiveness protocols for imaging in the management of ureteral calculous disease: AUA technology assessment. J Urol 2013;189:1203–1213.